...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International clinical psychopharmacology >A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment
【24h】

A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment

机译：阿立哌唑辅助治疗抗抑郁药的美军退伍军人慢性创伤后应激障碍的一项随机安慰剂对照试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Many individuals with post-traumatic stress disorder (PTSD) experience persistent symptoms despite pharmacological treatment with antidepressants. Several open-label monotherapy and adjunctive studies have suggested that aripiprazole (a second-generation antipsychotic) may have clinical utility in PTSD. However, there have been no randomized placebo-controlled trials of aripiprazole use for PTSD. We thus conducted a pilot randomized controlled trial of adjunctive aripiprazole versus placebo among Veterans with chronic PTSD serving in the US military since 11 September 2001 to assess the feasibility, safety, tolerability, and therapeutic potential of aripiprazole. Sixteen Veterans were randomized, and 14 completed at least 4 weeks of the study; 12 completed the entire 8-week trial. Outcome measures included the Clinician-Administered PTSD Scale (CAPS), PTSD Checklist, Beck Depression Inventory, Second Edition, and Positive and Negative Syndrome Scale scores. Aripiprazole was well-tolerated in this cohort, and improvements in CAPS, PTSD Checklist, Beck Depression Inventory, Second Edition, and Positive and Negative Syndrome Scale scores were as hypothesized. Although CAPS change scores did not reach statistical significance, aripiprazole outperformed placebo by 9 points on the CAPS in the last observation carried forward analysis compared with the placebo group (n = 7 per group), and by 20 points in the group randomized to aripiprazole that completed the entire study (n = 5) compared with the placebo group (n = 7). Results suggest promise for aripiprazole as an adjunctive strategy for the treatment of PTSD. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
机译：尽管有抗抑郁药的药理治疗，许多患有创伤后应激障碍（PTSD）的人仍会持续出现症状。几项开放标签的单一疗法和辅助研究表明，阿立哌唑（第二代抗精神病药）可能在PTSD中具有临床效用。但是，尚无阿立哌唑用于PTSD的随机安慰剂对照试验。因此，我们从2001年9月11日开始在美国军方中患有慢性PTSD的退伍军人中进行了辅助阿立哌唑和安慰剂的随机对照试验，以评估阿立哌唑的可行性，安全性，耐受性和治疗潜力。 16名退伍军人被随机分配，其中14名完成了至少4周的研究; 12位用户完成了整个8周的试用期。结果指标包括临床医生管理的PTSD量表（CAPS），PTSD清单，贝克抑郁量表，第二版以及阳性和阴性综合征量表得分。阿立哌唑在该队列中的耐受性良好，并假设CAPS，PTSD清单，贝克抑郁量表，第二版以及阳性和阴性综合征量表得分均有改善。尽管CAPS的变化评分未达到统计学显着性，但与安慰剂组相比，在最后一次观察中，阿立哌唑在CAPS上比安慰剂组高9分（每组n = 7），而在随机分组使用阿立哌唑的组中，阿立哌唑比安慰剂组高20分与安慰剂组（n = 7）相比，完成了整个研究（n = 5）。结果表明，阿立哌唑有望作为PTSD的辅助治疗策略。版权所有（C）2015 Wolters Kluwer Health，Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号